We are live on
!
Find out more
MIM
MetLife Investment Management Portfolio holdings
AUM
$22.1B
1-Year Est. Return
45.54%
This Fund
S&P 500
This Quarter
Est. Return
+9.69%
1 Year Est. Return
+45.54%
3 Year Est. Return
+139.2%
5 Year Est. Return
+180.26%
10 Year Est. Return
–
AUM
$13.7B
AUM Growth
-$178M
(-1.3%)
Cap. Flow
-$1.14B
Cap. Flow
% of AUM
-8.27%
Top 10 Holdings %
Top 10 Hldgs %
25.57%
Holding
3,040
New
254
Increased
776
Reduced
1,044
Closed
100
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Meta Platforms (Facebook)
META
|
+$14.9M |
| 2 |
Palo Alto Networks
PANW
|
+$14.8M |
| 3 |
iShares MSCI EAFE ETF
EFA
|
+$9.08M |
| 4 |
iShares Russell 2000 ETF
IWM
|
+$7.73M |
| 5 |
Crown Holdings
CCK
|
+$5.37M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
iShares iBoxx $ Investment Grade Corporate Bond ETF
LQD
|
+$901M |
| 2 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$71.6M |
| 3 |
Apple
AAPL
|
+$11.2M |
| 4 |
iShares Russell 1000 Growth ETF
IWF
|
+$10.7M |
| 5 |
Vanguard Short-Term Bond ETF
BSV
|
+$8.77M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.03% |
| 2 | Healthcare | 12.56% |
| 3 | Financials | 11.14% |
| 4 | Consumer Discretionary | 11.03% |
| 5 | Industrials | 9.55% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1601
Rocket Pharmaceuticals
RCKT
$363M
| $574K | ﹤0.01% |
28,906
+720
| +3% | +$14.5K |
|
|
EXAS
1602
DELISTED
Exact Sciences
EXAS
| $574K | ﹤0.01% |
6,115
+1,233
| +25% | +$96.2K |
|
|
LPRO
1603
DELISTED
Open Lending Corp
LPRO
| $574K | ﹤0.01% |
54,618
-4,109
| -7% | -$36.3K |
|
|
STEL
1604
DELISTED
Stellar Bancorp
STEL
| $574K | ﹤0.01% |
25,073
+562
| +2% | +$13.1K |
|
1605
Inspire Medical Systems
INSP
$1.66B
| $573K | ﹤0.01% |
1,766
-13,227
| -88% | -$3.78M |
|
1606
Logitech
LOGI
$14.8B
| $573K | ﹤0.01% |
9,636
| – | – |
|
1607
Napco Security Technologies
NSSC
$1.35B
| $572K | ﹤0.01% |
16,507
| – | – |
|
|
PWSC
1608
DELISTED
PowerSchool Holdings, Inc.
PWSC
| $572K | ﹤0.01% |
29,874
+5,035
| +20% | +$96.2K |
|
1609
AerCap
AER
$23.8B
| $572K | ﹤0.01% |
9,000
| – | – |
|
1610
Arcus Biosciences
RCUS
$3.66B
| $571K | ﹤0.01% |
28,134
+1,203
| +4% | +$22.9K |
|
1611
SFL Corp
SFL
$1.65B
| $571K | ﹤0.01% |
61,230
| – | – |
|
|
EVBG
1612
DELISTED
Everbridge, Inc. Common Stock
EVBG
| $569K | ﹤0.01% |
21,154
+529
| +3% | +$14.3K |
|
1613
Scholastic
SCHL
$784M
| $568K | ﹤0.01% |
14,613
-1,010
| -6% | -$39.2K |
|
|
CBAY
1614
DELISTED
Cymabay Therapeutics
CBAY
| $567K | ﹤0.01% |
+51,802
| New | +$482K |
|
1615
FIGS
FIGS
$2.42B
| $567K | ﹤0.01% |
68,535
| – | – |
|
1616
National Bank Holdings
NBHC
$1.94B
| $566K | ﹤0.01% |
19,494
+3,784
| +24% | +$118K |
|
1617
Weis Markets
WMK
$1.75B
| $565K | ﹤0.01% |
8,795
| – | – |
|
1618
Sabre
SABR
$892M
| $565K | ﹤0.01% |
176,970
+7,152
| +4% | +$25.8K |
|
1619
S&T Bancorp
STBA
$1.81B
| $564K | ﹤0.01% |
20,743
| – | – |
|
1620
Employers Holdings
EIG
$873M
| $564K | ﹤0.01% |
15,066
+607
| +4% | +$23.8K |
|
1621
Aehr Test Systems
AEHR
$4.36B
| $563K | ﹤0.01% |
+13,653
| New | +$448K |
|
1622
RB Global
RBA
$15.7B
| $563K | ﹤0.01% |
9,382
+5,604
| +148% | +$316K |
|
1623
Gulfport Energy Corp
GPOR
$3.01B
| $562K | ﹤0.01% |
5,353
-1,057
| -16% | -$98K |
|
1624
Global Net Lease
GNL
$1.86B
| $559K | ﹤0.01% |
54,350
| – | – |
|
|
APLS
1625
DELISTED
Apellis Pharmaceuticals
APLS
| $558K | ﹤0.01% |
6,126
-42,949
| -88% | -$3.71M |
|
Similar funds
BA
FAM
VARA
CHP
EIM
HHII
MetLife Investment Management's Q2 2023 Portfolio in Review
As of Q2 2023, MetLife Investment Management held 3,040 positions worth $13.7B, down 1.3% from $13.9B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
MetLife Investment Management withdrew a net $1.14B in Q2 2023, closing 100 positions and reducing 1,044 holdings. Its most notable exit was Evoqua Water Technologies Corp. Common Stock, an estimated $3.05M position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 22% a quarter earlier, followed by Healthcare and Financials.
Against the trend, MetLife Investment Management opened a new position in Knife River worth $2.46M.
- MetLife Investment Management's largest Q2 2023 buy was Knife River: 56,478 shares worth $2.46M.
- MetLife Investment Management added most to Meta Platforms (Facebook) in Q2 2023, an estimated $14.9M increase.
- MetLife Investment Management's biggest Q2 2023 reduction was iShares iBoxx $ Investment Grade Corporate Bond ETF, cutting an estimated $901M.
- MetLife Investment Management fully exited Evoqua Water Technologies Corp. Common Stock in Q2 2023, selling an estimated $3.05M.
- MetLife Investment Management's ten largest holdings make up 26% of its $13.7B portfolio in Q2 2023.
- MetLife Investment Management opened 254 new positions and closed 100 in Q2 2023.
- MetLife Investment Management's portfolio value fell 1.3% quarter-over-quarter to $13.7B.
Based on MetLife Investment Management's 13F filing for Q2 2023, filed 10 Aug 2023.